Expected net present value of sample information: From burden to investment

Medical Decision Making

Volumn 32, Issue 3, 2012, Pages

  Hall, Peter S ^a,c,d   Edlin, Richard ^a   Kharroubi, Samer ^b   Gregory, Walter ^c   McCabe, Christopher ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bayesian decision theory; cost effectiveness analysis; expected value of information; research design

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; COMPARATIVE STUDY; DECISION MAKING; ECONOMICS; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL INFORMATION SYSTEM; HUMAN; INCOME; MEDICAL INFORMATICS; MONTE CARLO METHOD; NONBIOLOGICAL MODEL; QUALITY ADJUSTED LIFE YEAR; STATISTICS; THEORETICAL MODEL; UNITED KINGDOM;

ALGORITHMS; BAYES THEOREM; DECISION MAKING; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH PLANNING; HOSPITAL INFORMATION SYSTEMS; HUMANS; INCOME; MEDICAL INFORMATICS; MODELS, ORGANIZATIONAL; MODELS, THEORETICAL; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 84861829485     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12443010     Document Type: Article

References (22)

1. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999 ; 18 (3). 341-64
2. Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient?. Health Aff. 2005 ; 24 (1). 93-101
3. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Economics. 2007 ; 16 (2). 195-209
4. Eckermann S, Willan AR. The option value of delay in health technology assessment. Med Decis Making. 2008 ; 28 (3). 300-5
5. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Medl Decis Making. 2004 ; 24 (2). 207-27
6. McKenna C, Claxton K. Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Med Decis Making. :
7. McCabe CJ, Stafinski T, Edlin R, Menon D. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics. 2010 ; 28 (2). 143-52
8. Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011 ; 29 (5). 415-32
9. Eckermann S, Willan AR. Time and expected value of sample information wait for no patient. Value Health. 2008 ; 11 (3). 522-6
10. McCabe C, Claxton K, O'Hagan A. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement. Int J Technol Assess Health Care. 2008 ; 24 (2). 140-5
11. Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess. 2004 ; 8 (27). 1-78
12. Griffin S, Welton NJ, Claxton K. Exploring the research decision space: the expected value of information for sequential research designs. Med Decis Making. 2010 ; 30 (2). 155-62
13. R, Development, Core, Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: URL: http://www.R-project.org
14. Oakley JE, O'Hagan A. Probabilistic sensitivity analysis of complex models: a Bayesian approach. J Roy Stat Soc B (Stat Methodol). 2004 ; 66 (3). 751-69
15. Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008 ; 28 (1). 21-32
16. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 ; 13 (15 Pt 1). 4429-34
17. Office of National Statistics. Interim life tables for England and Wales 2006-2008. Actuary's Regent Street, Sheffield, England. Available from: URL: http://www.statistics.gov.uk
18. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 ; 357 (26). 2666-76
19. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer. 2007 ; 97 (4). 479-85
20. NHS Reference Costs. London: Department of Health ; 2010 :
21. Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010 ; 12 (1). 66-74
22. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007 ; 16 (6). 1073-81